2005
DOI: 10.1016/j.jpain.2005.01.131
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of lamotrigine in painful diabetic neuropathy: Results from two large double-blind trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2006
2006
2009
2009

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Of the second‐generation anticonvulsants, RCTs have been conducted examining lamotrigine, oxcarbazepine, topiramate, and zonisamide for the treatment of DPNP. Lamotrigine demonstrated efficacy in one clinical trial of 59 patients with DPNP [48], but results of intention‐to‐treat analyses were negative in two recent large trials of DPNP [49]. For oxcarbazepine, one positive and several unpublished trials [50] have been accompanied by an announcement that its development as a potential treatment for neuropathic pain has been discontinued.…”
Section: Resultsmentioning
confidence: 99%
“…Of the second‐generation anticonvulsants, RCTs have been conducted examining lamotrigine, oxcarbazepine, topiramate, and zonisamide for the treatment of DPNP. Lamotrigine demonstrated efficacy in one clinical trial of 59 patients with DPNP [48], but results of intention‐to‐treat analyses were negative in two recent large trials of DPNP [49]. For oxcarbazepine, one positive and several unpublished trials [50] have been accompanied by an announcement that its development as a potential treatment for neuropathic pain has been discontinued.…”
Section: Resultsmentioning
confidence: 99%
“…61 Most recently, two large multicenter trials in patients with diabetic neuropathy each failed to demonstrate pain reduction compared with placebo in intention-to-treat analyses of the primary endpoint of pain reduction, and a relatively high dropout rate may have reflected poorer tolerability at higher dosages (Ͼ 300 mg daily). 84 Therapeutic liabilities include relatively high incidence of rash and drug-drug interactions.…”
Section: Lamotriginementioning
confidence: 99%